Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$89.4m

Aclaris Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Aclaris Therapeutics has a total shareholder equity of $157.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $197.4M and $40.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$119.11m
EquityUS$157.18m
Total liabilitiesUS$40.23m
Total assetsUS$197.41m

Recent financial health updates

Recent updates

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Aug 25
Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow

Jun 08

Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

May 28
Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

Aclaris Therapeutics EPS misses by $0.29, beats on revenue

May 07

Financial Position Analysis

Short Term Liabilities: ACRS's short term assets ($128.9M) exceed its short term liabilities ($31.0M).

Long Term Liabilities: ACRS's short term assets ($128.9M) exceed its long term liabilities ($9.3M).


Debt to Equity History and Analysis

Debt Level: ACRS is debt free.

Reducing Debt: ACRS has no debt compared to 5 years ago when its debt to equity ratio was 13.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ACRS has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 4.2% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.